The influence of immunosuppressants on direct ‐acting antiviral therapy is dependent on hepatitis C virus genotype

ConclusionFor patients with HCV GT2a, GT3a or GT4a infection, mTOR‐based immunosuppressive therapy may be beneficial, whereas CNI‐based therapy may be more efficacious in GT1b patients.This article is protected by copyright. All rights reserved.

Source: Transplant Infectious Disease - November 7, 2017 Category: Transplant Surgery Authors: Alexandra Frey, Katja Piras ‐Straub, Andreas Walker, Jörg Timm, Guido Gerken, Kerstin Herzer Tags: Original Report Source Type: research